Respiratory

Pediatric experts emphasize the importance of asthma action plans, medication readiness, and school-based support to help children with asthma stay healthy and active during the academic year.

Can you guess the diagnosis?

Nirsevimab reduced RSV-related illness by up to 98% and lowered the amount of hospitalizations and health care use among healthy term infants in a real-world study.

Can you diagnose this patient? Take our poll and find out! Then check back for the full case, differential diagnosis, and correct diagnosis.

Pediatric pulmonologist Richard Wong, DO, outlines how school environments can complicate asthma management for children across all age groups.

According to research from 2021 to 2023, approximately 50% of adolescents who vaped had tried to quit in the last 12 months.

Mycoplasma pneumoniae caused 1 in 2 pediatric pneumonia hospitalizations in 2024, with sharp increases seen across all age groups, according to a recent CDC MMWR report.

The final recommendation sign off decision will go to HHS secretary Robert F. Kennedy Jr.

Donna Hallas, PhD, PPCNP-BC, CPNP, PMHS, FAANP, FAAN, shares her thoughts on how PNPs can implement evidence-based strategies to encourage parents to vaccinate their children.

Octavio Ramilo, MD, joins us once again to discuss potential benefits of RSV vaccination beyond disease prevention and to explain how to speak with patients about vaccines and uptake.

In this video, the last in a 3-part series, panelists discuss future directions in the field and the importance of multispecialty collaboration.

In this video, part 2 in a 3-part series, panelists discuss clesrovimab's recent approval and gaps in clinician education.

In this video, the first in a 3-part series, panelists discuss recent advancements in RSV management.

The authors noted that comparisons between PDA management strategies is crucial for informing optimal approaches to the PDA.

The AI-enabled, wearable device is the first FDA-approved, drug-free solution for nasal congestion and allergies in children ages 12 and up.

These findings come as many health care professionals still report limited confidence and inconsistent practices regarding RSV immunization discussions.

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

Albuterol-budesonide (Airsupra; AstraZeneca) resulted in a 47% reduction in severe exacerbations in mild asthma vs albuterol alone.

Severe RSV disease in 2022–2023 was most likely to occur in infants under 6 months and older children with pulmonary or neurologic conditions.

"Early identification of high-risk neonates may enable targeted strategies to support respiratory health," stated the study investigators.

"These findings support Advisory Committee on Immunization Practices’ recommendations for maternal vaccination or nirsevimab to protect against severe RSV disease in infants," wrote the MMWR study investigators.

On physical examination, the patient appeared to be in significant respiratory distress. Her oxygen saturation was 96% on high-flow nasal cannula.

Current prevention strategies include 2 injectables for infants and young children, namely palivizumab and nirsevimab.

Can you diagnose this patient? Take our poll and find out! Then check back for the full case, differential diagnosis, and correct diagnosis.

Nirsevimab significantly reduces RSV-related hospitalizations, ICU admissions, and LRTIs in infants, but doesn’t shorten hospital stays, according to a recent study.